Study of CKD-215 and D215 in Adults With BRCA-mutated Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Exclusion Criteria

• •Have a gastrointestinal disease(Crohn's disease, ulcer etc.) history that can effect drug absorption or surgery
• •Patients with central nervous system metastases, unless clinically stable after treatment
• •CTCAE Grade 3 or higher adverse events(e.g., anemia, neutropenia, dysgeusia, cough, leukopenia, thrombocytopenia) related to D215
• •Subjects who are unable to participate in this clinical trial at the discretion of the investigator